Avenue Therapeutics' BAER-101 acquired by Axsome Therapeutics for epilepsy treatment.
ByAinvest
Thursday, Nov 6, 2025 7:19 am ET1min read
AXSM--
Avenue Therapeutics has agreed to sell its majority-owned subsidiary, Baergic Bio, and the global rights to BAER-101 (also known as AZD7325) to Axsome Therapeutics. BAER-101 is a novel oral GABAA α2,3 subtype-selective receptor PAM, which was originally licensed by Baergic from AstraZeneca. Axsome intends to evaluate the compound as a potential treatment for epilepsy.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet